



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : <b>C07D 211/46, A61K 31/445</b>		A1	(11) International Publication Number: <b>WO 94/26714</b> (43) International Publication Date: 24 November 1994 (24.11.94)
(21) International Application Number: <b>PCT/US94/04974</b>			[GB/GB]; Glycobiology Institute, Dept. of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU (GB).
(22) International Filing Date: 11 May 1994 (11.05.94)			BUTTERS, Terry, D. [GB/GB]; Glycobiology Institute, Dept. of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU (GB).
(30) Priority Data: 08/061,645 13 May 1993 (13.05.93) 08/102,654 5 August 1993 (05.08.93)		US US	(74) Agents: MEYER, Scott, J. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).
(60) Parent Application or Grant (63) Related by Continuation US 08/102,654 (CON) Filed on 5 August 1993 (05.08.93)			(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FL, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(71) Applicants ( <i>for all designated States except US</i> ): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US). MONSANTO COMPANY [US/US]; 800 North Lindbergh Boulevard, St. Louis, MO 63167 (US).			Published <i>With international search report.</i>
(72) Inventors; and (75) Inventors/Applicants ( <i>for US only</i> ): PLATT, Frances, M. [GB/GB]; Glycobiology Institute, Dept. of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU (GB). NEISES, Gabrielle, R. [US/US]; 13939 Meursault, Chesterfield, MO 63017 (US). DWEK, Raymond, A.			
(54) Title: NOVEL DEOXYGALACTONOJIRIMYCIN DERIVATIVES			
(57) Abstract			
Novel N-alkyl derivatives of deoxygalactonojirimycin are provided in which said alkyl contains from 3-6 carbon atoms. These novel compounds are useful for selectively inhibiting glycolipid synthesis.			

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

NOVEL DEOXYGALACTONOJIRIMYCIN DERIVATIVESCross-reference to Related Application

This application is a continuation-in-part of  
5 copending application Ser. No. 08/061,645, filed May 13,  
1993.

Background of the Invention

10 This invention relates to novel N-alkyl derivatives of deoxygalactonojirimycin (DGJ) in which said alkyl groups contain from 3-6 carbon atoms. These novel compounds are useful for selectively inhibiting glycolipid synthesis.

15 In applicants' copending application Ser. No. 08/061,645, filed May 13, 1993, N-alkyl derivatives of deoxynojirimycin (DNJ) having 2-8 carbon atoms in the alkyl groups are disclosed as effective inhibitors of glycolipid biosynthesis. These derivatives of DNJ were 20 also previously known to be inhibitors of the N-linked oligosaccharide processing enzymes,  $\alpha$ -glucosidase I and II. Saunier et al., J. Biol. Chem. 257, 14155-14166 (1982); Elbein, Ann. Rev. Biochem. 56, 497-534 (1987). As glucose analogues, they also have potential to 25 inhibit glucosyltransferases. Newbrun et al., Arch. Oral Biol. 28, 516-536 (1983); Wang et al., Tetrahedron Lett. 34, 403-406 (1993). Their inhibitory activity against the glucosidases has led to the development of these compounds as antihyperglycemic agents and 30 antiviral agents. See, e.g., PCT Int'l. Appln. WO 87/03903 and U.S. Patents: 4,065,562; 4,182,767; 4,533,668; 4,639,436; 4,849,430; 5,011,829; and 5,030,638.

Brief Description of the Invention

In accordance with the present invention, novel N-alkyl derivatives of deoxygalactonojirimycin (DGJ) are provided in which said alkyl contains from 3-6 carbon atoms and preferably from 4-6 carbon atoms. These novel compounds are useful for selectively inhibiting glycolipid synthesis. The length of the N-alkyl chain has been found to be important to said inhibitory activity since the non-alkylated DGJ and the N-methyl and N-ethyl derivatives of DGJ were each found to be inactive for such inhibition. The N-propyl derivative of DGJ was partially active. Thus, a minimum alkyl chain length of 3 carbon atoms has been found to be essential for efficacy. Illustratively, the biosynthesis of glycolipids in cells capable of producing glycolipids can be selectively inhibited by treating said cells with a glycolipid inhibitory effective amount of any of these novel compounds.

The active N-alkyl derivatives of DGJ have a significant advantage since, unlike the previously described N-alkyl derivatives of DNJ, they selectively inhibit biosynthesis of glycolipids without effect either on the maturation of N-linked oligosaccharides or lysosomal glucocerebrosidase. For example, in contrast to N-butyl DNJ, the N-butyl DGJ of the present invention surprisingly does not inhibit the processing  $\alpha$ -glucosidases I and II or lysosomal  $\beta$ -glucocerobrosidase. Likewise, the only prior reported experimental evidence using deoxygalactonojirimycin indicates that N-alkylation (N-heptyldeoxygalactonojirimycin) provides a modest increase in the affinity towards certain  $\beta$ -glucosidases [Legler & Pohl, Carb. Res. 155, 119 (1986)]. The inhibitory results described herein for the novel N-alkylated deoxy<sup>99/1075</sup>nojirimycin analogues in which the alkyl contains from 3 to 6 carbon atoms were

unexpected in view of the corresponding activity of related iminosugar compounds.

Further uniqueness of the present invention is seen by the finding that the exemplary N-butyl and N-hexyl derivatives of DGJ completely prevented glycolipid biosynthesis, whereas the N-butyl derivatives of mannose, fucose and N-acetylglucosamine were without effect on glycolipid biosynthesis.

The inhibitory effect of these compounds on the biosynthesis of glycolipids is illustrated herein in the myeloid cell line HL-60 and in the lymphoid cell line H9. These are well-known, widely distributed and readily available human cell lines. For example, HL-60 cells are promyelocytic cells described by Collins et al., Nature 270, 347-349 (1977). They are also readily available from the American Type Culture Collection, Rockville, MD, U.S.A., under accession number ATCC CCL 240. H9 cells are of lymphoid origin described by Gallo and Popovic, Science 224, 497-500 (1984). They are also readily available from the same depository under accession number ATCC HTB 176.

The inhibition of glycolipid biosynthesis by these N-alkyl derivatives of DGJ is further demonstrated herein by the reduction of the binding of cholera toxin to the illustrative cell line H9 when cultured in the presence on N-butyl DGJ. These compounds thus are also useful as anti-microbial agents by inhibiting the surface expression on glycolipid receptors for bacteria and bacterial toxins as illustrated hereinafter in Tables 1 and 2, respectively.

The inhibitory effect upon the biosynthesis of glycolipids is further illustrated by the ability of the N-butyl and N-hexyl derivatives of DGJ to offset glucoceramide accumulation in a standard, state-of-the-art *in vitro* model of Gaucher's disease. In this model, the murine macrophage cell line WEHI-3B was cultured in the presence of an irreversible glucocerebrosidase

inhibitor, conduritol  $\beta$  epoxide (CBE), to mimic the inherited disorder found in Gaucher's disease. WEHI-3B cells are described in Cancer Res. 37, 546-550 (1977), and are readily available from the American Type Culture Collection, Rockville, MD, under accession number ATCC TIB 68. The compounds of the invention prevent lysosomal glycolipid storage which is useful for the management of Gaucher's disease and other glycolipid storage disorders as illustrated hereinafter in Table 3.

Gaucher's disease is an autosomal recessive disorder characterized by an impaired ability to degrade glucocerebroside (glucosyl ceramide, Glc-Cer) due to mutations in the gene encoding  $\beta$ -glucocerebrosidase ( $\beta$ -D-glucosyl-N-acylsphingosine glucohydrolase, EC 3.2.1.45). This defect results in the lysosomal accumulation of Glc-Cer in cells of the macrophage-monocyte system [Barranger and Ginns, in The Metabolic Basis of Inherited Diseases, ed. Scriver et al., pp. 1677-1698, McGraw-Hill, New York, (1989); Beutler, Science 256, 794-799 (1992)]. By slowing the rate of glycolipid synthesis, the impaired catabolism of Glc-Cer can be offset, thereby leading to the maintenance of a balanced level of Glc-Cer.

The clinical management of Gaucher's disease currently relies upon either symptomatic treatment of patients or enzyme replacement therapy [Beutler, Proc. Natl. Acad. Sci. USA 90, 5384-5390 (1993)]. In view of the prohibitive cost of enzyme replacement therapy and the requirement for intravenous administration of glucocerebrosidase, an orally available alternative therapy based around substrate deprivation constitutes a useful alternative. Since NB-DGJ exhibits fewer complicating enzyme inhibitory characteristics than  $\alpha$ - and  $\beta$ -glucosidase inhibitors, it constitutes a preferable alternative to NB-DNJ for therapeutic management of Gaucher's disease and other glycolipid storage disorders.

Detailed Description of the Invention

While the specification concludes with claims  
5 particularly pointing out and distinctly claiming the subject matter regarded as forming the invention, it is believed that the invention will be better understood from the following illustrative detailed description of the invention taken in conjunction with the accompanying  
10 drawings in which:

FIG. 1 shows by one dimensional thin layer chromatography (1D-TLC) a comparison of N-alkylated imino sugars as inhibitors of glycolipid biosynthesis.  
15 1D-TLC separation was made of HL-60 total cellular lipids labelled with [<sup>14</sup>C]-palmitic acid. Cells were treated with either 0.5 mM N-butyl deoxynojirimycin (NB-DNJ), N-butyl deoxymannojirimycin (NB-DMJ), N-butyl deoxygalactonojirimycin (NB-DGJ) or N-butyl 2-acetamido-  
20 1,2,5-trideoxy-1,5-imino-D-glucitol (NB-NAG) or untreated (UT). Glycolipid biosynthesis inhibition was detected by the lack of Glc-Cer, gangliosides and an unknown species (indicated with arrows). Glc-Cer migration was confirmed by inclusion of a [<sup>14</sup>C]-Glc-Cer standard on the TLC. The radiolabelled lipid species  
25 were visualized by autoradiography.

FIG. 2, in three parts, A, B and C, shows 2D-TLC analysis of HL-60 cells treated with either NB-DNJ or  
30 NB-DGJ. 2D-TLC separation was made of total HL-60 lipids labelled with [<sup>14</sup>C]-palmitic acid. Cells were treated with either 0.5 mM NB-DNJ or NB-DGJ or untreated (UT). Lipids were assigned as follows (untreated cells, lefthand panel, FIG. 2A): 1, gangliosides; 2, lysophosphatidylcholine; 3, ceramide phosphorylcholine;  
35 4, ceramide phosphorylethanamine; 5, phosphatidylcholine; 6, phosphatidylinositol; 7,

phosphatidylethanolamine; 8, phosphatidylglycerol; 9, diglycosylceramide; 10, monoglycosylceramide; 11, cholesterol/fatty acids/neutral lipids; N and N\* are unknowns; and 0 is the sample origin. Following NB-DNJ and NB-DGJ treatment (middle and righthand panels, FIGS. 2B and 2C, respectively) species 1 (gangliosides); 9 (diglycosylceramide); 10 (monoglycosylceramide) and N\* (unknown) were absent. The radiolabelled lipids were visualized by autoradiography.

10

FIG. 3 shows the dose dependent effects of NB-DNJ and NB-DGJ on glycolipid biosynthesis. 1D-TLC analysis was made of total cellular lipids. HL-60 cells were labelled with [<sup>14</sup>C]-palmitic acid in the presence or 15 absence (UT) of NB-DNJ or NB-DGJ at the indicated concentrations ( $\mu$ M). The migration position of [<sup>14</sup>C]-Glc-Cer is indicated by arrows. The lipids were visualized by autoradiography.

20

FIG. 4, in two parts, A and B, shows the effects of increasing DNJ and DGJ N-alkyl chain length on inhibition of glycolipid biosynthesis. 1D-TLC analysis was made of total cellular lipids. HL-60 cells were treated with [<sup>14</sup>C]-palmitic acid in the presence or 25 absence (UT) of either DNJ, or the N-ethyl, N-methyl, N-propyl, N-butyl and N-hexyl derivatives of DNJ (lefthand panel, FIG. 4A) or DGJ, or the N-ethyl, N-methyl, N-propyl, N-butyl and N-hexyl derivatives of DGJ (righthand panel, FIG. 4B) at 0.5 mM concentration. The 30 migration position of [<sup>14</sup>C]-Glc-Cer is indicated with arrows. The lipids were visualized by autoradiography.

FIGS. 5 and 6 show the analysis of NB-DNJ and NB-DGJ in an in vitro Gaucher's disease model. 35 Specifically, FIG. 5 shows the 1D-TLC analysis of glycolipids from WEHI-3B cells treated with either NB-DNJ or NB-DGJ, at the indicated concentrations ( $\mu$ M), and

visualized by chemical detection (see methods hereinafter).

FIG. 6, in eight parts, A through H, shows the  
5 transmission electron microscopy of WEHI-3B cell  
lysosomes: FIG. 6A, untreated; FIG. 6B, conduritol  $\beta$   
epoxide (CBE) treated; FIG. 6C, CBE and 500  $\mu$ M NB-DNJ;  
FIG. 6E, CBE and 50  $\mu$ M NB-DNJ; FIG. 6G, CBE and 5  $\mu$ M NB-  
DNJ; FIG. 6D, CBE and 500  $\mu$ M NB-DGJ; FIG. 6F, CBE and 50  
10  $\mu$ M NB-DGJ; FIG. 6H, CBE and 5  $\mu$ M NB-DGJ. The scale bar  
at the lower right hand corner of FIG. 6H is applicable  
to all of FIGS. 6A through H and represents 0.1  $\mu$ M.

FIG. 7 shows the effect of NB-DGJ on N-linked  
15 oligosaccharide processing. Specifically, it shows Endo  
H sensitivity of gp120 expressed in Chinese hamster  
ovary (CHO) cells in the presence or absence (-) of  
either NB-DNJ or NB-DGJ (0.5 mM and 5 mM). The arrows  
indicate the molecular weight of the untreated gp120  
20 (120 kDa) and post endo H digestion (60 kDa). An  
additional band of low molecular weight (approximately  
60 kDa) was present in some lanes and is a non-specific  
protein precipitated by the solid phase matrix.

25 FIG. 8 is a graphical representation that shows, in  
three parts, A, B and C, the effect of imino sugar  
analogues on glycolipid and glycoprotein metabolizing  
enzyme activity. Enzyme activity was determined in the  
presence of the following test compounds: DNJ, ( $\blacklozenge$ ); NB-  
30 DNJ, ( $\blacksquare$ ); DGJ, ( $\blacktriangle$ ); NB-DGJ, ( $\bullet$ ) at concentrations shown  
(see methods hereinafter). FIG. 8A, UDP-glucose:N-  
acylsphingosine glucosyltransferase; FIG. 8B,  $\beta$ -  
glucocerebrosidase; FIG. 8C, processing  $\alpha$ -glucosidase.  
Enzymatic activity is expressed as a percentage of  
35 control reactions that contained no test compound.

FIG. 9 shows the laser desorption mass spectrometry of N-butyl deoxygalactonojirimycin with a molecular weight of 220 (M+H) and obtained in greater than 95% purity.

5

FIG. 10 shows the  $^1\text{H}$  NMR spectrum of N-butyl deoxygalactonojirimycin.

FIG. 11 is a graphical representation of a cholera toxin binding assay and shows on the y-axis the % reduction in cholera toxin binding sites per cell for H9 cells in which the cholera toxin was fluorescein conjugated and in which the levels of binding to the cell surfaces of untreated (ut) cells and cells treated 15 with N-butyl deoxygalactonojirimycin (NB-DGJ) or, for comparison, N-butyl deoxynojirimycin (NB-DNJ), at various levels shown on the x-axis (mg/ml), were measured by flow cytometry.

20 In order to further illustrate the invention, the following detailed examples were carried out although it will be understood that the invention is not limited to these specific examples or the details therein.

25

### EXAMPLES

### MATERIALS & METHODS

#### Compounds:

30

N-Butyldeoxynojirimycin (NB-DNJ) was obtained from Searle/Monsanto (St. Louis, MO, U.S.A.). Deoxygalactonojirimycin (DGJ), deoxyfuconojirimycin (DFJ), deoxymannojirimycin (DMJ), and 2-acetamido-1,2,5-35 trideoxy-1,5-imino-D-glucitol (NAG), were obtained from Cambridge Research Biochemicals (Northwich, Cheshire, U.K.). DGJ, DFJ, DMJ and NAG were reductively N-

alkylated in the presence of palladium black under hydrogen using the appropriate aldehyde by conventional procedure as described by Fleet et al., FEBS Lett. 237, 128-132 (1988). The reaction mixture was filtered 5 through Celite and the solvent removed by evaporation under vacuum. The resulting N-alkylated analogues were purified by ion-exchange chromatography (Dowex® AG50-X12, H<sup>+</sup> form) in 2M NH<sub>3</sub> (aq) and the solvent removed by evaporation. These compounds were lyophilised and 10 analysed by 1D <sup>1</sup>H NMR at 500 MHz on a Varian Unity 500 spectrophotometer and by matrix assisted laser desorption (Finnegan). All compounds synthesised were greater than 95% pure. The following are representative examples of the synthesis of the foregoing N-alkylated 15 compounds as used hereinafter.

Example 1

In a representative example of the preparation of 20 the N-butyl deoxygalactonojirimycin, 30 mg (184 μmol) of deoxygalactonojirimycin was dissolved in 1 ml of 50 mM sodium acetate buffer, pH 5.0, to which 20 mg of palladium black was added. A hydrogen atmosphere was maintained in the reaction vessel and 100 μl (1.1 mM) 25 of butyraldehyde was introduced. The reaction was stirred for 16 hr. at room temperature (ca. 20°C). The reaction was stopped by filtration through a bed (1 g) of Celite (30-80 mesh) and the reaction products were separated by chromatography using a column containing 4 30 ml of packed Dowex® AG50-X12 (H<sup>+</sup> form) resin. The N-butyl deoxygalactonojirimycin was eluted from the chromatography column with 2M ammonia. Its molecular mass was 220 (M+H) as determined by laser desorption mass spectrometry and its chemical structure was 35 confirmed by 1D <sup>1</sup>H NMR as shown in Figures 9 and 10, respectively.

Example 2

The synthesis procedure and compound analysis of Example 1 was repeated except that caproaldehyde was 5 substituted for an equivalent amount of butyraldehyde for analogous preparation of N-hexyl deoxygalactonojirimycin. Its molecular mass was 248 (M+H) as determined by laser desorption mass spectrometry and its chemical structure was confirmed by 10 1D  $^1\text{H}$  NMR.

Example 3

The synthesis procedure and compound analysis of 15 Example 1 was repeated except that propanoyl aldehyde was substituted for an equivalent amount of butyraldehyde for analogous preparation of N-propyl deoxygalactonojirimycin. Its molecular mass was 206 (M+H) as determined by laser desorption mass 20 spectrometry and its chemical structure was confirmed by 1D  $^1\text{H}$  NMR.

The N-alkylated deoxygalactonojirimycin compounds prepared in the foregoing illustrative Examples 1 to 3 25 were obtained in overall yields of 68-74% based on the starting deoxygalactonojirimycin and were greater than 95% pure.

Enzymes and Enzyme Assays:

30 Porcine liver  $\alpha$ -glucosidase I and rat liver  $\alpha$ -glucosidase II were purified to homogeneity and assayed by conventional procedure using a [ $^{14}\text{C}$ ]-glucose labelled  $\text{Glc}_3\text{Man}_9\text{GlcNAc}_2$  substrate as previously described by 35 Karlsson et al., J. Biol. Chem. 268, 570-576 (1993).  $\beta$ -D-Glucosyl-N-acylsphingosine glucohydrolase (glucocerebrosidase) was isolated from human placenta

and purified to homogeneity according to published standard methods [Furbish et al., Proc. Natl. Acad. Sci. USA 74, 3560-3563 (1977); Dale and Beutler, Ibid. 73, 4672-4674 (1976)]. Glucocerebrosidase activity was measured by adding enzyme (5-50  $\mu$ l) to a sonicated suspension of buffer (50  $\mu$ l of 50 mM sodium citrate/sodium phosphate buffer, pH 5.0) containing glucosyl ceramide (1 mM), Triton® X-100 non-ionic surfactant (0.25% v/v) and sodium taurodeoxycholate (0.6% v/v) that had been previously dried under nitrogen from chloroform:methanol (2:1 v/v) solutions. After incubation at 37°C for 15-60 min., the reaction was stopped by the addition of 500  $\mu$ l of chloroform:methanol and the phases separated by centrifugation. The upper phase was washed twice with Folch theoretical lower phase [Folch et al., J. Biol. Chem. 226, 497-509 (1957)] desalted using AG50-X12 ion-exchange resin and dried under vacuum. The reaction products were separated by high performance anion exchange chromatography (Dionex BioLC System) and detected by pulsed amperometry. The amount of enzyme-released glucose was calculated from peak areas by applying experimentally determined response factors for glucose relative to an included reference monosaccharide [Butters et al., Biochem. J. 279, 189-195 (1991)].

UDP-glucose:N-acylsphingosine glucosyltransferase (EC 2.4.1.80) activity was measured in rat brain homogenates and mouse macrophage tissue cultured cell (WEHI-3B) homogenates using a method adapted as follows from published conventional procedures [Vunnam and Radin, Chem. & Phys. of Lipids 26, 265-278 (1980); Shukla and Radin, Arch. Biochem. Biophys. 283, 372-378 (1990)]: Dioleoylphosphatidylcholine and cerebroside liposomes containing 200 nmol ceramides Type IV (Sigma) were added to a reaction mixture (100  $\mu$ l) composed of 40 mM 2-[N-morpholino]ethanesulfonic acid (MES) buffer, pH 6.5, 5 mM MnCl<sub>2</sub>, 2.5 mM MgCl<sub>2</sub>, 1 mM NADH and 8  $\mu$ M UDP-

[<sup>14</sup>C]-glucose (318 mCi/mmol, Amersham International, Amersham, U.K.). After incubation at 37°C for 1-2 hr. the reaction was stopped by the addition of EDTA (25 mM) and KCl (50 mM). Radiolabelled glycolipids were extracted with 500 µl of chloroform:methanol (2:1 v/v) for 10 min. and the phases separated. The lower phase was washed twice with Folch theoretical upper phase and portions taken for scintillation counting. When imino sugars were tested for inhibitory activity, these were added at appropriate concentrations to homogenates and preincubated for 10 min. before sonication with ceramide containing liposomes. Control reactions were performed with liposomes containing no ceramide to measure the activity of transfer to endogenous acceptors.

15

Glycolipid Analysis:

HL-60 cells were cultured by conventional procedure as previously described by Platt et al., Eur. J. Biochem. 208, 187-193 (1992). HL-60 cells at 5 x 10<sup>4</sup> cells/ml were cultured in the presence or absence of imino sugars for 24 hr. For labelling, the two dimensional thin layer chromatography (2D-TLC) conventional method of Butters and Hughes was followed [In Vitro 17, 831-838 (1981)]. Briefly, [<sup>14</sup>C]-palmitic acid (56.8 mCi/mmol, ICN/Flow) was added as a sonicated preparation in foetal calf serum (FCS, Techgen, London, U.K., 0.5 µCi/ml) and the cells cultured for a further 3 days maintaining the imino sugars in the medium. The cells were harvested, washed three times with phosphate buffered saline (PBS), extracted in 1 ml chloroform:methanol (2:1 v/v) and separated by 1 dimensional TLC, loading equal counts (1D-TLC, chloroform:methanol:water (65:25:4)). For two dimensional separations the one dimensional separation was performed as described above, the plate dried

overnight under vacuum and separated in the second dimension using a solvent of tetrahydrofuran: dimethoxymethane:methanol:water (10:6:4:1). Plates were air dried and exposed to Hyperfilm-MP high 5 performance autoradiography film (Amersham).

Cell Culture and Metabolic Labelling:

The culture of CHO cells expressing soluble 10 recombinant gp120 (from Dr. P. Stevens, MRC AIDS Directed Programme Reagent Project) and the radiolabelling of these cells was carried out by conventional procedure as described by Karlsson et al., J. Biol. Chem. 268, 570-576 (1993). Briefly, CHO cells 15 were harvested mechanically, washed three times with phosphate buffered saline, 0.1M pH 7.2 (PBS) and resuspended in methionine- and cysteine-free RPMI-1640 medium (ICN-Flow Laboratories, High Wycombe, Bucks, U.K.) supplemented with 1% dialysed FCS. Cells ( $10^7$ /ml) 20 were preincubated in the presence or absence of NB-DNJ or NB-DGJ for 1 hr prior to the addition of 100  $\mu$ Ci/ml Tran<sup>35</sup>S-label (ICN-Flow) for 4 hr. The supernatants were collected and concentrated tenfold using a 30 kDa cut-off membrane (Amicon, Danvers, MA, U.S.A.).

25

Immunoprecipitation:

Immunoprecipitations were performed by conventional procedure as described by Karlsson supra. Supernatants 30 were incubated with the mAb ABT 1001 monoclonal antibody (American Biotechnologies Inc., Cambridge, MA, U.S.A.) at 0.5  $\mu$ g/100  $\mu$ l of supernatant for 30 min. at room temperature followed by sheep anti-mouse IgG1-coated magnetic beads (Dynal Ltd., Wirral, Merseyside, U.K., 35 1.2  $\times$   $10^7$  beads per sample) for 1 hr. at 4°C. The beads were washed three times with 2% Triton® X-100 in PBS and three times with PBS. Gp120 was eluted in 100  $\mu$ l

reducing SDS-PAGE sample buffer with heating (95°C, 5 min.). Each sample was divided into two equal aliquots and 25 µl of dH<sub>2</sub>O added to give a final volume of 50 µl. To one half of each sample 2 µl of endoglycosidase H (endo H, 1 unit/ml, Boehringer Mannheim Ltd., Lewes, Sussex, U.K.) was added and the other half left untreated. Digestion was performed at 37°C for 18 hr. and terminated by the addition of 50 µl of SDS-PAGE reducing sample buffer (95°C, 5 min.).

10

Glycopeptide Analysis:

HL-60 and BW5147 cells were cultured in RPMI-1640 and 10% FCS. The cells were incubated for 30 min. in 15 the presence or absence of 2 mM NB-DNJ or NB-DGJ in reduced glucose RPMI-1640 medium (Flow), supplemented with 1% dialysed FCS. [<sup>3</sup>H]-mannose (16.5 Ci/mmol, Amersham) was added at 200 µCi/ml and the cells cultured for a further 3 hr. Washed cell pellets were 20 resuspended in 50 mM TrisHCl buffer, pH 7.5, containing 10 mM CaCl<sub>2</sub> and 0.02% sodium azide and heated at 100°C for 5 min. After cooling, Pronase® enzyme was added to 0.04% (w/v final concentration) and incubated for 96 hr. at 37°C under toluene with aliquots of Pronase® added at 25 each 24 hr. period. The digestion was stopped by boiling for 5 min., and glycopeptides recovered by centrifugation at 13000 g for 10 min. Samples were fractionated by Con A-Sepharose® chromatography according to conventional procedure of Foddy et al., 30 Biochem. J. 233, 697-706 (1986).

In Vitro Gaucher's Disease Model:

The in vitro Gaucher's disease model was prepared 35 as follows: WEHI-3B cells (American Type Culture Collection, Rockville, MD, U.S.A.) were maintained in logarithmic phase growth for 14 days in RPMI-1640

medium, 10% FCS, in the presence or absence of 50  $\mu$ M conduritol  $\beta$  epoxide (CBE, Toronto Research Chemicals, Downsview, Canada) with or without NB-DNJ or NB-DGJ. Cells were passaged every 3 days and compound 5 concentrations maintained throughout. Equal cell numbers ( $5 \times 10^6$ ) were harvested, extracted in 1 ml chloroform: methanol (2:1 v/v) overnight at 4°C, the extracts centrifuged, the chloroform:methanol extract retained and the pellet re-extracted as above for 2 hr. 10 at room temperature. Pooled extracts were dried under nitrogen, re-dissolved in 10  $\mu$ l chloroform:methanol (2:1 v/v) and separated by 1D-TLC in chloroform:methanol:water (10:6:4:1). Plates were air dried and visualized using  $\alpha$ -naphthol (1% w/v in 15 methanol) followed by 50% (v/v) sulphuric acid.

Transmission Electron Microscopy:

Cells for electron microscopy were harvested (1 x 20  $10^7$  cells per treatment), washed three times in serum free RPMI-1640 medium and fixed in medium containing 2% glutaraldehyde (v/v) and 20 mM Hepes (v/v) on ice for 2 hr. Cells were washed in 0.1 M cacodylate buffer containing 20 mM calcium chloride (w/v). Cells were 25 post-fixed with 1% osmium tetroxide in 25 mM cacodylate buffer (w/v) containing 1.5% potassium ferrocyanide (w/v) for 2 hr. on ice. Samples were dehydrated through an ethanol series, transferred to propylene oxide and embedded in Embed 800 (Electron Microscopy Sciences, PA, 30 U.S.A.). The sections were stained with uranyl acetate/lead citrate and observed with a Hitachi 600 microscope at 75 kv.

Analysis of cholera toxin binding to the H9 human lymphoid cell line following three days treatment with NB-DNJ or NB-DGJ:

5       Methods: Cells were maintained in logarithmic phase growth in RPMI-1640 medium. Cholera toxin B chain (Sigma) was conjugated to fluorescein isothiocyanate (Sigma) and flow cytometric analysis was carried out by conventional procedure as described by Platt et al.,  
10 Eur. J. Biochem. 208, 187-193 (1992). Analysis was performed on a FACScan Cytometer (Becton Dickinson, Sunnyvale, CA, USA). Data on viable cells were collected on a four decade  $\log_{10}$  scale of increasing fluorescence intensity. The data are presented as  
15 percent reduction in cholera toxin bindings sites per cell on the y-axis against compound concentration on the x-axis. The specificity of cholera toxin : cell surface binding was established by inhibiting this interaction with a one hundred fold molar excess of GMI derived  
20 oligosaccharide, Gal $\beta$ GalNAc $\beta$ 4(NeuAc $\alpha$ 3)Gal $\beta$ 4Glc $\beta$ 3Cer.

RESULTS

Comparison of N-alkylated imino sugars as inhibitors of  
25 glycolipid biosynthesis:

The glucose analogue, NB-DNJ and four pyranose analogues (NB-DMJ, mannose analogue; NB-DFJ, fucose analogue; NB-DGJ, galactose analogue; and NB-NAG, N-30 acetylglucosamine analogue) were assessed by the above methods for their capacities to inhibit the metabolic incorporation of radiolabelled palmitate into glycolipids in HL-60 cells at a 500  $\mu$ M compound concentration using 1D-TLC analysis (Fig. 1). In  
35 addition to NB-DNJ, the only analogue which specifically inhibited glycolipid biosynthesis was NB-DGJ. All other analogues were without effect. Both NR-DNJ and NB-DGJ

inhibited the biosynthesis of Glc-Cer, gangliosides and an unknown lipid species in agreement with the previous observations with NB-DNJ described in copending application Ser. No. 08/061,645. To confirm that NB-DNJ and NB-DGJ had comparable effects on the complete spectrum of glycolipids in this cell line, 2D-TLC was performed to resolve further the individual glycolipid species (Fig. 2). A total depletion of glycolipid species was achieved with both 500  $\mu$ M NB-DNJ and NB-DGJ. Specifically, gangliosides, the unknown lipid (N\*) and both the mono and dihexaside species were absent following treatment with either compound. Phospholipid composition and relative abundance were comparable, irrespective of treatment, consistent with the previous observations in copending application Ser. No. 08/061,645 that N-alkylated imino sugars have no effect on sphingomyelin or phospholipid biosynthesis. When the two analogues were compared at a range of concentrations by 1D-TLC (Fig. 3) both analogues exhibited complete glycolipid inhibition between 50  $\mu$ M and 500  $\mu$ M concentrations, although partial inhibition occurred with both compounds at concentrations as low as 0.5-5  $\mu$ M. Both analogues were non-cytotoxic in the dose range tested.

25

Effects of increasing DNJ and DGJ N-alkyl chain length on inhibition of glycolipid biosynthesis:

A series of N-alkylated DNJ and DGJ derivatives were compared for their abilities to inhibit glycolipid biosynthesis (Fig. 4A and 4B, respectively) by 1D-TLC. The non-alkylated imino sugars and the N-methyl DNJ, N-ethyl DNJ, N-methyl DGJ and N-ethyl DGJ had no effect on glycolipid biosynthesis. The N-propyl analogues of both parent compounds showed partial inhibitory activity, whereas the N-butyl and N-hexyl derivatives of DNJ and DGJ completely inhibited glycolipid biosynthesis, as

determined by the loss of detectable Glc-Cer. These data were therefore in agreement with the data from the previous application Ser. No. 08/061,645 (where the N-methyl derivative was compared with N-butyl and N-hexyl 5 DNJ). There is a minimal N-alkyl chain length requirement to achieve full inhibition of glycolipid biosynthesis, with butyl and hexyl being optimal.

Analysis of NB-DGJ in an in vitro Gaucher's disease 10 model:

The WEHI-3B murine macrophage cell line can be induced to resemble Gaucher's cells by treatment with the irreversible glucocerebrosidase inhibitor CBE. NB-15 DNJ and NB-DGJ were compared in their ability to prevent the accumulation of Glc-Cer in this system (Fig. 5). Both analogues prevented CBE induced glycolipid storage in the 5-50  $\mu$ M dose range. These data therefore demonstrate that NB-DGJ is as effective as NB-DNJ in preventing glycolipid storage in this in vitro Gaucher's 20 disease model. The status of the lysosomes from cells treated with either NB-DNJ or NB-DGJ was assessed by transmission electron microscopy (Fig. 6). It was found that both analogues prevented the glycolipid 25 accumulation observed in the lysosomes of cells treated with CBE.

Specificity of NB-DGJ for the glycolipid biosynthetic pathway:

30 The CHO cell line is unique in that it lacks significant levels of the Golgi endomannosidase which acts to circumvent  $\alpha$ -glucosidase I and II inhibition [Karsson et al., J. Biol. Chem. 268, 570-576 (1993); 35 Hiraizumi et al., J. Biol. Chem. 268, 9927-9935 (1993)]. As a consequence, it offers an unambiguous cellular system in which to test  $\alpha$ -glucosidase inhibition. NB-

DNJ was previously tested in this cell line expressing recombinant gp120 and it was found that it results in the maintenance of glucosylated high mannose oligosaccharides on gp120 which are fully sensitive to 5 endo H [Karlsson et al., supra].

Analysis of the N-linked oligosaccharides of gp120 expressed in CHO cells was performed in the presence or absence of NB-DNJ or NB-DGJ (Fig. 7). Treatment of CHO cells with 0.5 mM or 5 mM NB-DNJ resulted in fully endo 10 H sensitive gp120 N-linked glycans in contrast to the untreated gp120 which was partially sensitive to endo H. This partial sensitivity of untreated gp120 to endo H is because gp120 carries approximately fifty percent high mannose N-linked oligosaccharides per molecule [Mizuuchi 15 et al., Biochem. J. 254, 599-603 (1988); Mizuuchi et al., Biomed. Chrom. 2, 260-270 (1988)]. However, when the galactose analogue, NB-DGJ, was tested in this system, at 0.5 mM and 5 mM concentrations, gp120 remained partially sensitive to endo H and was 20 indistinguishable from the untreated gp120 molecules. This suggested that the galactose analogue was not acting as an inhibitor of  $\alpha$ -glucosidases I and II.

To examine the effect on endogenous glycoprotein synthesis, radiolabelled glycopeptides were isolated 25 from treated HL-60 and murine BW5147 cells and analysed for their affinity for Con A-Sepharose®. This procedure efficiently resolves tetra- and tri-antennary complex N-glycans from bi-antennary and high mannose/hybrid N-glycans [Foddy et al., Biochem. J. 233, 697-706 (1986)]. 30 Addition of NB-DNJ changes the affinity of glycopeptides eluting from the Con A-Sepharose® column (Table 4) as a result of processing glucosidase inhibition. Thus the proportion of unbound glycans (tetra- and tri-antennary species) decreases, and a corresponding increase is 35 found in the proportion of high mannose/hybrid glycans that are tightly bound to Con A-Sepharose® and eluted with 500 mM methylmannoside. Similar gross changes in

glycopeptide composition following treatment with  $\alpha$ -glucosidase inhibitors are well established [Moore and Spiro, J. Biol. Chem. 265, 13104-13112 (1990)]. The galactose analogue, NB-DGJ, showed an unchanged glycopeptide profile by Con A-Sepharose® chromatography (Table 4). To confirm these data, glucosidase inhibition was measured directly in vitro using a mixture of purified  $\alpha$ -glucosidases I and II (Fig. 8). Whereas NB-DNJ inhibited glucosidase I and II with an IC<sub>50</sub> of 0.36  $\mu$ M, NB-DGJ was only weakly inhibitory (IC<sub>50</sub> of 2.13 mM, Table 5). These data provide substantial evidence that in both in vitro  $\alpha$ -glucosidase assays and in intact cellular system assays NB-DGJ does not inhibit N-linked oligosaccharide processing.

DNJ and its N-alkylated derivatives are inhibitors of the purified lysosomal glucocerebrosidase enzyme required for the cleavage of Glc-Cer to glucose and ceramide [Osiecki-Newman et al., Biochim. Biophys. Acta. 915, 87-100 (1987)]. In recent tests with the in vitro Gaucher's disease model in co-pending application Ser. No. 08/061,645, it was observed that WEHI-3B cells incubated in the absence of CBE but in the presence of NB-DNJ accumulated Glc-Cer. It was therefore apparent that the N-butyl derivative of DNJ was also acting as an inhibitor of glucocerebrosidase in a cellular environment. The inhibitory activity of NB-DNJ and NB-DGJ was therefore directly measured to investigate quantitatively their capacities to inhibit human placental glucocerebrosidase (Table 5). NB-DNJ provided moderate inhibition of catalysis with an IC<sub>50</sub> of 0.52 mM while NB-DGJ did not inhibit enzyme activity even at the highest concentration tested (1 mM). In terms of percent enzyme inhibition achieved with the two analogues, 1 mM NB-DNJ resulted in 90% inhibition while 1 mM NB-DGJ was non-inhibitory (Fig. 8), thereby further confirming the advantageous and unexpected selective

inhibitory activity of NB-DGJ compared to that of NB-DNJ.

Inhibition of UDP-glucose:N-acylsphingosine  
5 glucosyltransferase:

The determination of transferase activity using rat brain or mouse macrophage tissue cultured cells followed saturation kinetics for both exogenously added ceramide acceptor and UDP-glucose donor. Under these conditions both N-butylated DNJ and DGJ were moderate inhibitors of glucose transfer, ( $IC_{50}$  2.95 mM and 60.88 mM, respectively, Table 5) whereas their unmodified parent homologues were not inhibitory at the highest concentration tested 6.1 and 5.0 mM, respectively, Fig. 8).

Analysis of cholera toxin binding to the H9 human  
lymphoid cell line treated with NB-DGJ:

20

The activity of the representative N-butyl deoxygalactonojirimycin (NB-DGJ) for inhibiting the surface expression of glycolipid receptors for bacteria and bacterial toxins was illustrated by subjecting H9 cells to cholera toxin binding sites in the presence of varying concentrations of the NB-DGJ. As a specific probe, advantage was taken of the GM1 binding specificity of the cholera toxin B chain [van Heyningen, Nature 249, 415-417 (1974); Karlsson, Ann. Rev. Biochem. 30 58, 309-350 (1989)]. The binding of cholera toxin to H9 cells cultured in the presence of NB-DGJ was reduced by approximately 70% (Fig. 11). This was consistent with the loss of GM1 from the cell surface and provided further evidence for the inhibition of glycolipid biosynthesis by NB-DGJ, even though by comparison it was less than the approximately 90% reduction (Fig. 11) obtained with the N-butyl deoxynojirimycin (NB-DNJ).

These results demonstrate that the imino sugar derivatives have use as anti-microbial agents by inhibiting the surface expression of glycolipid receptors for bacteria and bacterial toxins as shown in  
5 Tables 1 and 2, respectively.

Table 1  
GLYCOSPHINGOLIPID RECEPTORS FOR BACTERIAL CELLS

	Microorganism	Target Issue	Presumed Specificity
5	<i>E. coli</i>	Urinary	Gal $\alpha$ 4Gal $\beta$
10	<i>E. coli</i>	Urinary	GlcNAc $\beta$
	<i>Propionibacterium</i>	Skin/Intestine	Gal $\beta$ 4Glc $\beta$
15	Several bacteria	Diverse	Gal $\beta$ 4Glc $\beta$
	<i>Streptococcus pneumoniae</i>	Respiratory	GlcNAc $\beta$ 3Gal
20	<i>E. coli</i> CFA/I	Intestine	NeuAca $\beta$
	<i>E. coli</i>	Urinary	NeuAca $\beta$ 3Gal
	<i>E. coli</i>	Intestine	NeuGca $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer GalNAc $\beta$ 4(NeuAca $\beta$ 3)- Gal $\beta$ 4Glc $\beta$ Cer
25	<i>Staphylococcus saprophyticus</i>	Urinary	Gal $\beta$ 4GlcNAc
30	<i>Actinomyces naeslundi</i>	Mouth	Gal $\beta$ , GalNAc $\beta$ , Gal $\beta$ 3GalNAc $\beta$ , GalNAc $\beta$ 3Gal $\beta$
35	<i>Pseudomonas</i>	Respiratory	GalNAc $\beta$ 4Gal
	<i>Neisseria gonorrhoeae</i>	Genital	Gal $\beta$ 4Glc $\beta$ NeuAca $\beta$ 3Gal $\beta$ 4GlcNAc

Table 2

## GLYCOSPHINGOLIPID RECEPTORS FOR BACTERIAL TOXINS

	Microorganism	Toxin	Target Tissue	Presumed Receptor Sequence
5				
10	<i>Vibrio cholerae</i>	Cholera toxin	Small Intestine	Gal $\beta$ 3GalNAc $\beta$ 4-(NeuAc $\alpha$ 3)Gal- $\beta$ 4Glc $\beta$ Cer
15	<i>E. coli</i>	Heat-labile toxin	Intestine	Gal $\beta$ 3GalNAc $\beta$ 4-(NeuAc $\alpha$ 3)Gal- $\beta$ 4Glc $\beta$ Cer
20	<i>Clostridium tetani</i>	Tetanus toxin	Nerve	Gal $\beta$ 3GalNAc $\beta$ 4-(NeuAc $\alpha$ 8Neu-Ac $\alpha$ 3)Gal $\beta$ 4Glc- $\beta$ Cer
25	<i>Clostridium botulinum</i>	Botulinum toxin A and E	Nerve Membrane	NeuAc $\alpha$ 8NeuAc-3Gal $\beta$ 3GalNAc $\beta$ -4(NeuAc $\alpha$ 8Neu-Ac $\alpha$ 3)Gal $\beta$ 4Glc- $\beta$ Cer
30	<i>Clostridium botulinum</i>	Botulinum toxin B, C and F	Nerve Membrane	NeuAc $\alpha$ 3Gal $\beta$ 3-GalNAc $\beta$ 4(Neu-Ac $\alpha$ 8NeuAc $\alpha$ 3)-Gal $\beta$ 4Glc $\beta$ Cer
35	<i>Clostridium botulinum</i>	Botulinum toxin B	Nerve Membrane	Gal $\beta$ Cer
40	<i>Clostridium perfringens</i>	Delta toxin	Cell lytic	GalNAc $\beta$ 4-(NeuAc $\alpha$ 3)Gal $\beta$ -4Glc $\beta$ Cer
45	<i>Clostridium difficile</i>	Toxin A	Large Intestine	Gal $\alpha$ 3Gal $\beta$ Glc-NAc $\beta$ 3Gal $\beta$ 4-Glc $\beta$ Cer
50	<i>Shigella dysenteriae</i>	Shiga toxin	Large Intestine	Gal $\alpha$ 4Gal $\beta$ Cer Gal $\alpha$ 4Gal $\beta$ 4Glc- $\beta$ Cer GlcNAc $\beta$ 4Glc-NAC
55	<i>E. coli</i>	Vero toxin or Shiga-like toxin	Intestine	Gal $\alpha$ 4Gal $\beta$ 4-Glc $\beta$ Cer

Table 3  
HEREDITARY GLYCOLIPID STORAGE DISORDERS

	Disease	Lipid Accumulation	Enzyme Defect
5	Gaucher's	Glucocerebroside	Glucocerebroside- $\beta$ -glucosidase
10	Ceramide Lactoside Lipidosis	Ceramide Lactoside	Ceramidelactoside- $\beta$ -galactosidase
15	Fabry's	Ceramide Trihexoside	Ceramidetrihexoside- $\alpha$ -galactosidase
20	Tay-Sach's	Ganglioside GM2	Hexosaminidase A
25	Sandhoff's	Globoside and GM2	Hexosaminidase A and B
30	General Gangliosidosis	Ganglioside GM1	$\beta$ -Galactosidase
	Fucosidosis	H-isoantigen	$\alpha$ -Fucosidase
	Krabbe's	Galactocerebroside	Galactocerebroside- $\beta$ -galactosidase
	Metrachromatic Leukodystrophy	Sulfatide	Sulfatidase

TABLE 4

5      EFFECT OF IMINO SUGAR ANALOGUES ON OLIGOSACCHARIDE  
BIOSYNTHESIS

10	Cell Line	Treatment	Tetra- & Tri-antennary	Bi-antennary	Oligomannose & hybrid	Total $^3\text{H}$ -mannose recovered (cpm)
15	HL-60	untreated	28.3	18.7	53.0	666918
		NB-DNJ	19.5	20.0	60.5	913095
		NB-DGJ	28.1	17.7	54.2	844322
20	BW5147	untreated	46.1	5.6	48.3	476527
		NB-DNJ	26.8	4.9	68.3	686026
		NB-DGJ	40.4	7.2	52.4	706873

Cells were radiolabelled for 4 hours with [ $^3\text{H}$ ]-mannose in the presence or absence of compounds as shown above. Washed cells were exhaustively digested with Pronase® enzyme and resultant glycopeptides fractionated by Con A-Sepharose® chromatography as described hereinbefore. The percentage of radiolabelled glycopeptides that were non-bound (complex tetra- and tri-antennary N-glycans), eluted with 10 mM methylglucoside (complex bi-antennary N-glycans), or further eluted with 500 mM methylmannoside (oligomannose and hybrid N-glycans) were calculated from estimations of radioactivity recovered from pooled eluates.

TABLE 5

5            CONCENTRATIONS OF IMINO SUGAR ANALOGUES REQUIRED FOR  
 THE INHIBITION OF GLYCOLIPID AND GLYCOPROTEIN  
 METABOLISING ENZYMES

	Enzyme	DNJ	Compound NB-DNJ	IC <sub>50</sub> values DGJ	NB-DGJ
10	UDP-glucose:N-acylsphingosine glucosyltransferase	- †	2.95 mM	- †	60.88 mM
	β-glucocerebrosidase	2.43 mM	0.52 mM	- *	- *
	α-glucosidase I and II	nd	0.36 μM	nd	2.13 mM

15

20        \*     not inhibitory at 1 mM concentrations of compound.

†     not inhibitory at the highest concentration tested  
 (see Fig. 8).

nd     not determined.

25        Enzymes were assayed according to procedure described  
 hereinbefore using concentrations of analogues shown in  
 Fig. 8. The data from Fig. 8 were plotted on a  
 logarithmic scale for accurate estimations of IC<sub>50</sub>  
 values, shown above.

30

In addition to their use as inhibitors of glycolipid biosynthesis in cells, the inhibitory agents described herein also can be used for administration to patients afflicted with glycolipid storage defects by

5 conventional means, preferably in formulations with pharmaceutically acceptable diluents and carriers. These agents can be used in the free amine form or in their salt form. Pharmaceutically acceptable salt derivatives are illustrated, for example, by the HCl

10 salt. The amount of the active agent to be administered must be an effective amount, that is, an amount which is medically beneficial but does not present toxic effects which overweigh the advantages which accompany its use. It would be expected that the adult human daily dosage

15 would normally range from about one to about 100 milligrams of the active compound. The preferable route of administration is orally in the form of capsules, tablets, syrups, elixirs and the like, although parenteral administration also can be used. Suitable

20 formulations of the active compound in pharmaceutically acceptable diluents and carriers in therapeutic dosage form can be prepared by reference to general texts in the field such as, for example, Remington's Pharmaceutical Sciences, Ed. Arthur Osol, 16th ed.,

25 1980, Mack Publishing Co., Easton, PA., U.S.A.

Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other

30 examples be included within the scope of the appended claims.

## WHAT IS CLAIMED:

1. N-alkyldeoxygalactonojirimycin in which said alkyl contains from 3 to 6 carbon atoms.

5

2. The N-alkyldeoxygalactonojirimycin of Claim 1 in which the alkyl is butyl.

3. The N-alkyldeoxygalactonojirimycin of  
10 Claim 1 in which the alkyl is hexyl.

4. The N-alkyldeoxygalactonojirimycin of  
Claim 1 in which the alkyl is propyl.

15 5. The method of inhibiting the biosynthesis  
of glycolipids in cells capable of producing glycolipids  
comprising subjecting said cells to a glycolipid  
inhibitory effective amount of an N-alkyl derivative of  
deoxygalactonojirimycin in which said alkyl contains  
20 from 3-6 carbon atoms.

6. The method of Claim 5 in which the alkyl  
group contains from 4-6 carbon atoms.

25 7. The method of Claim 6 in which the alkyl  
group is butyl.

8. The method of Claim 6 in which the alkyl  
group is hexyl.

30

9. The method of Claim 5 in which the  
inhibitory effective amount is from about 50  $\mu$ M to about  
500  $\mu$ M.

35

10. The method of Claim 5 in which the  
glycolipid is a glucoceramide based glycosphingolipid.

11. The method of Claim 5 in which the glycolipid is a lysosomal glycolipid.

12. The method of Claim 5 in which the  
5 glycolipid is a glucoceramide accumulating in cells affected with Gaucher's disease.

13. The method of inhibiting the surface expression of glycolipid receptors for bacteria and  
10 bacterial toxins comprising subjecting cells susceptible to said expression to an effective amount for inhibiting said expression of an N-alkyl derivative of deoxygalactonojirimycin in which said alkyl contains from 3-6 carbon atoms.

15

14. The method of Claim 13 in which the alkyl group contains from 4-6 carbon atoms.

15. The method of Claim 14 in which the alkyl  
20 group is butyl.

16. The method of Claim 14 in which the alkyl group is hexyl.

25

17. The method of Claim 13 in which the inhibitory effective amount is from about 50  $\mu\text{M}$  to about 500  $\mu\text{M}$ .

18. The method of Claim 13 in which the  
30 bacterial toxin is cholera toxin.

1 / 11




FIG. I

2 / 11




FIG. 2B

FIG. 2A

FIG. 2C

8 / 11






FIG. 3



SUBSTITUTE SHEET (RULE 26)

FIG. 4B

FIG. 4A

5 / 11




FIG. 5

6 / 11




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG. 6E




FIG. 6F




FIG. 6G



FIG. 6H

7 / 11




FIG. 7

8 / 11




FIG. 8A




FIG. 8B

9 / 11






FIG. 8C

FIG. 9  
SUBSTITUTE SHEET (RULE 26)

10 / 11

FIG. 10



SUBSTITUTE SHEET (RULE 26)

11 / 11


**H9 Cells: Cholera Toxin Binding Assay**

FIG. 11

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 94/04974

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C07D211/46 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 536 402 (NIPPON SHINYAKU) 14 April 1993 see page 1, line 1 - page 2, line 18; claim; examples 3-4,23 -----	1-18

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

9 August 1994

19.08.94

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

## Authorized officer

Zervas, B

**INTERNATIONAL SEARCH REPORT**II. ~~Information on patent family members~~International application No.  
PCT/US 94/04974

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0536402	14-04-93	CA-A-	2086413	30-12-91